Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2025 08:00 ET | Source: KALA BIO, Inc.

KALA BIO to Present at Jefferies Global Healthcare Conference

ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative...
May 14, 2025 08:00 ET | Source: KALA BIO, Inc.

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data anticipated in 3Q 2025 -- -- Cash resources of $42.2 million as...
March 31, 2025 08:00 ET | Source: KALA BIO, Inc.

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

-- Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) -- -- Continuing enrollment into 2Q25; currently targeting topline data in 3Q25 -- ...
February 26, 2025 08:00 ET | Source: KALA BIO, Inc.

KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

ARLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
February 12, 2025 08:00 ET | Source: KALA BIO, Inc.

KALA BIO Announces Chief Executive Officer Transition

ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
December 30, 2024 08:00 ET | Source: KALA BIO, Inc.

KALA BIO Announces $10,750,000 Private Placement

ARLINGTON, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
November 27, 2024 08:00 ET | Source: KALA BIO, Inc.

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

ARLINGTON, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
November 12, 2024 08:00 ET | Source: KALA BIO, Inc.

KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update

-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results expected in 2Q 2025 -- -- Initiated five clinical trial sites for the...
August 08, 2024 08:00 ET | Source: KALA BIO, Inc.

KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

ARLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
August 06, 2024 08:00 ET | Source: KALA BIO, Inc.

KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update

-- Closed $12.5 million private placement financing led by SR One with participation from ADAR1 Capital Management and another life sciences-focused investor – -- Cash resources of $54.2 million as...